

Market Announcement

20 February 2026

Pacific Edge Limited (ASX: PEB) – Trading Halt

Trading in the securities of Pacific Edge Limited ('PEB') will be halted at the request of PEB, pending the release of an announcement by PEB.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Tuesday, 24 February 2026; or
- the release of the announcement to the market.

PEB's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

20 February 2026

To:	ASX Limited	NZ RegCo
	Level 27	11 Cable St
	39 Martin Place	Wellington
	Sydney NSW 2000	New Zealand
	Australia	issuer@nzregco.com
	TradingHaltsNZ@asx.com.au	

Request for trading halt: Pacific Edge ASX Code: PEB; NZX Code: PEB

We request a trading halt to be applied to our securities (ISIN: NZPEBE0002S1) under ASX Listing Rule 17.1 and NZX Listing Rule 9.9.1(a) and set out details of the request below as per the rules of each of ASX and NZX.

We would like the trading halt to commence from: prior to the market open today (Friday 20 February 2026).

Reasons for trading halt: Novitas, Pacific Edge's Medicare Administrative Contractor (MAC) is scheduled to hold a Contractor Advisory Committee (CAC) meeting commencing at 6pm on 19 February 2026, US ET (today, Friday 20 February 2026, 12:00pm NZST), a time when Pacific Edge's shares would normally be trading on both the NZX and ASX.

The meeting, between Novitas and urological experts, is to be held in public and will be streamed online.

It has been convened to discuss "*evidence for the use of urine-based biomarkers in patients with microhematuria*" and is designed to systematically capture expert opinion on the subject. Because CACs are generally convened ahead of developing new or substantially revised medical policy as a draft Local Coverage Determination (LCD), the content of the meeting (and its outcome) may have significant strategic implications for the future of Pacific Edge.

Specifically, comments made by experts or Novitas personnel during the meeting regarding the general utility of biomarkers for hematuria evaluation, the appropriate patient types and what physicians should do with a test result (among other things) could be indicative of whether the MAC is minded to develop a draft LCD supporting Medicare reimbursement of Cxbladder (or leave Cxbladder's current Medicare status unchanged as not eligible for reimbursement).

Pacific Edge therefore believes it is appropriate for trading in its shares to cease during the meeting and until the company has had time to assess its content and prepare an announcement that provides context to investors.

How long we want the trading halt to last: Until the earlier of PEB releasing a statement to the market regarding the CAC meeting, or the commencement of trading on the NZX on Tuesday, 24 February 2026. However, Pacific Edge expects to release this statement ahead of the market open on Monday 23 February 2026.

The event we expect to happen that will end the trading halt: The release of a statement to the market regarding the CAC meeting.

Other information necessary to inform the market about the trading halt or that ASX or NZ RegCo have requested. N/A

We confirm that we are not aware of any reason why the trading halt should not be granted.

Yours sincerely

DocuSigned by:
Grant Gibson
38EA090A715B41F...

Grant Gibson

Chief Financial Officer

Pacific Edge Limited